RCAS1 is a promising therapeutic target against cancer: Its multifunctional bioactivities and clinical significance

Kenzo Sonoda

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is a type II membrane protein that can induce apoptosis in immune cells, including peripheral lymphocytes and natural killer cells, after being converted to a secreted type by ectodomain shedding. So far, over 140 scientific reports have been published concerning the biological functions and clinical significance of RCAS1. Since RCAS1 not only helps tumor cells to evade immune surveillance but also induces cancer stromal tissue remodeling, RCAS1 is believed to exaggerate aggressive characteristics of human malignancies. Clinically, RCAS1 expression correlates with several pathological variables including tumor size, stage and invasion depth, and lymph node metastasis, and is a negative predictor of overall survival in 15 different kinds of cancer. RCAS1 is secreted in significantly greater quantities in serum of pleural effusion in cancer patients than noncancer patients, and its level is changed in response to treatment. Novel therapeutic strategies against cancer are now under development by targeting the intriguing biomarker RCAS1.

Original languageEnglish
Pages (from-to)261-267
Number of pages7
JournalExpert Review of Obstetrics and Gynecology
Volume7
Issue number3
DOIs
Publication statusPublished - May 1 2012

Fingerprint

Neoplasms
Therapeutics
Pleural Effusion
Natural Killer Cells
Membrane Proteins
Biomarkers
Lymph Nodes
Lymphocytes
Apoptosis
Neoplasm Metastasis
Antigens
Survival
Serum

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Reproductive Medicine
  • Obstetrics and Gynaecology
  • Maternity and Midwifery

Cite this

RCAS1 is a promising therapeutic target against cancer : Its multifunctional bioactivities and clinical significance. / Sonoda, Kenzo.

In: Expert Review of Obstetrics and Gynecology, Vol. 7, No. 3, 01.05.2012, p. 261-267.

Research output: Contribution to journalReview article

@article{76898d190a3b45bab8016a5c6b26c4db,
title = "RCAS1 is a promising therapeutic target against cancer: Its multifunctional bioactivities and clinical significance",
abstract = "Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is a type II membrane protein that can induce apoptosis in immune cells, including peripheral lymphocytes and natural killer cells, after being converted to a secreted type by ectodomain shedding. So far, over 140 scientific reports have been published concerning the biological functions and clinical significance of RCAS1. Since RCAS1 not only helps tumor cells to evade immune surveillance but also induces cancer stromal tissue remodeling, RCAS1 is believed to exaggerate aggressive characteristics of human malignancies. Clinically, RCAS1 expression correlates with several pathological variables including tumor size, stage and invasion depth, and lymph node metastasis, and is a negative predictor of overall survival in 15 different kinds of cancer. RCAS1 is secreted in significantly greater quantities in serum of pleural effusion in cancer patients than noncancer patients, and its level is changed in response to treatment. Novel therapeutic strategies against cancer are now under development by targeting the intriguing biomarker RCAS1.",
author = "Kenzo Sonoda",
year = "2012",
month = "5",
day = "1",
doi = "10.1586/eog.12.22",
language = "English",
volume = "7",
pages = "261--267",
journal = "Expert Review of Obstetrics and Gynecology",
issn = "1747-4108",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - RCAS1 is a promising therapeutic target against cancer

T2 - Its multifunctional bioactivities and clinical significance

AU - Sonoda, Kenzo

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is a type II membrane protein that can induce apoptosis in immune cells, including peripheral lymphocytes and natural killer cells, after being converted to a secreted type by ectodomain shedding. So far, over 140 scientific reports have been published concerning the biological functions and clinical significance of RCAS1. Since RCAS1 not only helps tumor cells to evade immune surveillance but also induces cancer stromal tissue remodeling, RCAS1 is believed to exaggerate aggressive characteristics of human malignancies. Clinically, RCAS1 expression correlates with several pathological variables including tumor size, stage and invasion depth, and lymph node metastasis, and is a negative predictor of overall survival in 15 different kinds of cancer. RCAS1 is secreted in significantly greater quantities in serum of pleural effusion in cancer patients than noncancer patients, and its level is changed in response to treatment. Novel therapeutic strategies against cancer are now under development by targeting the intriguing biomarker RCAS1.

AB - Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is a type II membrane protein that can induce apoptosis in immune cells, including peripheral lymphocytes and natural killer cells, after being converted to a secreted type by ectodomain shedding. So far, over 140 scientific reports have been published concerning the biological functions and clinical significance of RCAS1. Since RCAS1 not only helps tumor cells to evade immune surveillance but also induces cancer stromal tissue remodeling, RCAS1 is believed to exaggerate aggressive characteristics of human malignancies. Clinically, RCAS1 expression correlates with several pathological variables including tumor size, stage and invasion depth, and lymph node metastasis, and is a negative predictor of overall survival in 15 different kinds of cancer. RCAS1 is secreted in significantly greater quantities in serum of pleural effusion in cancer patients than noncancer patients, and its level is changed in response to treatment. Novel therapeutic strategies against cancer are now under development by targeting the intriguing biomarker RCAS1.

UR - http://www.scopus.com/inward/record.url?scp=84860587521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860587521&partnerID=8YFLogxK

U2 - 10.1586/eog.12.22

DO - 10.1586/eog.12.22

M3 - Review article

AN - SCOPUS:84860587521

VL - 7

SP - 261

EP - 267

JO - Expert Review of Obstetrics and Gynecology

JF - Expert Review of Obstetrics and Gynecology

SN - 1747-4108

IS - 3

ER -